Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
UNVC volume alert. Big buys coming in running on news.
UNIVEC announces entry into Transdermal Patch Marketplace.
Owings Mills, Maryland —January 17, 2012– Univec, Inc. (UNVC) a specialty pharmaceutical company, announces it has entered into the transdermal patch marketplace with the provision of Nicotine Replacement Therapy patches. Nicotine Replacement Therapy involves the use of products that provide low doses of nicotine but do not contain the toxins found in smoke. The goal is to relieve cravings for nicotine and ease the symptoms when someone stops using cigarettes and smokeless tobacco. Transdermal patch is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream.
David L. Dalton, President and CEO of Univec stated. “ We are delighted to continue making progress in our new business model. The National Drug Codes received from the FDA allows Univec to builds it’s own brand of products. The Transdermal patch can be used for different drug delivery system. It is a foundation to build and grow the company on some of our existing markets. We thank our associates, shareholders and investors for the support, confidence and patience they have shown the company. ”
About Univec
Univec, Inc. A minority business enterprise (MBE) is a Specialty Pharmaceutical Company that manufactures and distributes high cost Specialty Pharmaceuticals. Specialty Pharmaceuticals are high cost products that are not usually dispensed in retail pharmacies but require special handling and a complex pharmaceutical regime. The company is focused on diseases such as Sickle Cell Anemia, Cancer, HIV/Aids, Hepatitis C., Multiple Sclerosis, Hemophilia and Drug addiction.
PPSI (PHYSICIAN AND PHARMACEUTICAL SERVICES, INC.) a subsidiary of Univec promotes and pays for pharmaceutical products though its network of pharmacies. PPSI eliminates the need for the pharmaceutical companies to distribute actual drug samples to physicians reducing potential liability for the physician while maintaining clinical oversight and drug interaction checks for the patient. The company through it’s “StarterScript” allows in lieu of a physician sample, a voucher or a co-payment card to be provide to the patient for a trial supply of medication redeemed in any of the nearly 55,000 retail pharmacies utilizing the PPSI real-time processing system.
.0005's getting hit again, a little more volume and we'll see .0007 today. This is looking really good for a multiday run.
Next push should take us past .0005
UNVC .0005's getting hit!
News out:
UNIVEC announces entry into Transdermal Patch Marketplace.
Owings Mills, Maryland —January 17, 2012– Univec, Inc. (UNVC) a specialty pharmaceutical company, announces it has entered into the transdermal patch marketplace with the provision of Nicotine Replacement Therapy patches. Nicotine Replacement Therapy involves the use of products that provide low doses of nicotine but do not contain the toxins found in smoke. The goal is to relieve cravings for nicotine and ease the symptoms when someone stops using cigarettes and smokeless tobacco. Transdermal patch is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream.
David L. Dalton, President and CEO of Univec stated. “ We are delighted to continue making progress in our new business model. The National Drug Codes received from the FDA allows Univec to builds it’s own brand of products. The Transdermal patch can be used for different drug delivery system. It is a foundation to build and grow the company on some of our existing markets. We thank our associates, shareholders and investors for the support, confidence and patience they have shown the company. ”
About Univec
Univec, Inc. A minority business enterprise (MBE) is a Specialty Pharmaceutical Company that manufactures and distributes high cost Specialty Pharmaceuticals. Specialty Pharmaceuticals are high cost products that are not usually dispensed in retail pharmacies but require special handling and a complex pharmaceutical regime. The company is focused on diseases such as Sickle Cell Anemia, Cancer, HIV/Aids, Hepatitis C., Multiple Sclerosis, Hemophilia and Drug addiction.
PPSI (PHYSICIAN AND PHARMACEUTICAL SERVICES, INC.) a subsidiary of Univec promotes and pays for pharmaceutical products though its network of pharmacies. PPSI eliminates the need for the pharmaceutical companies to distribute actual drug samples to physicians reducing potential liability for the physician while maintaining clinical oversight and drug interaction checks for the patient. The company through it’s “StarterScript” allows in lieu of a physician sample, a voucher or a co-payment card to be provide to the patient for a trial supply of medication redeemed in any of the nearly 55,000 retail pharmacies utilizing the PPSI real-time processing system.
For those of you just getting here, here is the news. This is big.
UNIVEC announces entry into Transdermal Patch Marketplace.
Owings Mills, Maryland —January 17, 2012– Univec, Inc. (UNVC) a specialty pharmaceutical company, announces it has entered into the transdermal patch marketplace with the provision of Nicotine Replacement Therapy patches. Nicotine Replacement Therapy involves the use of products that provide low doses of nicotine but do not contain the toxins found in smoke. The goal is to relieve cravings for nicotine and ease the symptoms when someone stops using cigarettes and smokeless tobacco. Transdermal patch is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream.
David L. Dalton, President and CEO of Univec stated. “ We are delighted to continue making progress in our new business model. The National Drug Codes received from the FDA allows Univec to builds it’s own brand of products. The Transdermal patch can be used for different drug delivery system. It is a foundation to build and grow the company on some of our existing markets. We thank our associates, shareholders and investors for the support, confidence and patience they have shown the company. ”
About Univec
Univec, Inc. A minority business enterprise (MBE) is a Specialty Pharmaceutical Company that manufactures and distributes high cost Specialty Pharmaceuticals. Specialty Pharmaceuticals are high cost products that are not usually dispensed in retail pharmacies but require special handling and a complex pharmaceutical regime. The company is focused on diseases such as Sickle Cell Anemia, Cancer, HIV/Aids, Hepatitis C., Multiple Sclerosis, Hemophilia and Drug addiction.
PPSI (PHYSICIAN AND PHARMACEUTICAL SERVICES, INC.) a subsidiary of Univec promotes and pays for pharmaceutical products though its network of pharmacies. PPSI eliminates the need for the pharmaceutical companies to distribute actual drug samples to physicians reducing potential liability for the physician while maintaining clinical oversight and drug interaction checks for the patient. The company through it’s “StarterScript” allows in lieu of a physician sample, a voucher or a co-payment card to be provide to the patient for a trial supply of medication redeemed in any of the nearly 55,000 retail pharmacies utilizing the PPSI real-time processing system.
UNVC running on news
UNIVEC announces entry into Transdermal Patch Marketplace.
Owings Mills, Maryland —January 17, 2012– Univec, Inc. (UNVC) a specialty pharmaceutical company, announces it has entered into the transdermal patch marketplace with the provision of Nicotine Replacement Therapy patches. Nicotine Replacement Therapy involves the use of products that provide low doses of nicotine but do not contain the toxins found in smoke. The goal is to relieve cravings for nicotine and ease the symptoms when someone stops using cigarettes and smokeless tobacco. Transdermal patch is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream.
David L. Dalton, President and CEO of Univec stated. “ We are delighted to continue making progress in our new business model. The National Drug Codes received from the FDA allows Univec to builds it’s own brand of products. The Transdermal patch can be used for different drug delivery system. It is a foundation to build and grow the company on some of our existing markets. We thank our associates, shareholders and investors for the support, confidence and patience they have shown the company. ”
About Univec
Univec, Inc. A minority business enterprise (MBE) is a Specialty Pharmaceutical Company that manufactures and distributes high cost Specialty Pharmaceuticals. Specialty Pharmaceuticals are high cost products that are not usually dispensed in retail pharmacies but require special handling and a complex pharmaceutical regime. The company is focused on diseases such as Sickle Cell Anemia, Cancer, HIV/Aids, Hepatitis C., Multiple Sclerosis, Hemophilia and Drug addiction.
PPSI (PHYSICIAN AND PHARMACEUTICAL SERVICES, INC.) a subsidiary of Univec promotes and pays for pharmaceutical products though its network of pharmacies. PPSI eliminates the need for the pharmaceutical companies to distribute actual drug samples to physicians reducing potential liability for the physician while maintaining clinical oversight and drug interaction checks for the patient. The company through it’s “StarterScript” allows in lieu of a physician sample, a voucher or a co-payment card to be provide to the patient for a trial supply of medication redeemed in any of the nearly 55,000 retail pharmacies utilizing the PPSI real-time processing system.
UNVC running on news!
UNIVEC announces entry into Transdermal Patch Marketplace.
Owings Mills, Maryland —January 17, 2012– Univec, Inc. (UNVC) a specialty pharmaceutical company, announces it has entered into the transdermal patch marketplace with the provision of Nicotine Replacement Therapy patches. Nicotine Replacement Therapy involves the use of products that provide low doses of nicotine but do not contain the toxins found in smoke. The goal is to relieve cravings for nicotine and ease the symptoms when someone stops using cigarettes and smokeless tobacco. Transdermal patch is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream.
David L. Dalton, President and CEO of Univec stated. “ We are delighted to continue making progress in our new business model. The National Drug Codes received from the FDA allows Univec to builds it’s own brand of products. The Transdermal patch can be used for different drug delivery system. It is a foundation to build and grow the company on some of our existing markets. We thank our associates, shareholders and investors for the support, confidence and patience they have shown the company. ”
About Univec
Univec, Inc. A minority business enterprise (MBE) is a Specialty Pharmaceutical Company that manufactures and distributes high cost Specialty Pharmaceuticals. Specialty Pharmaceuticals are high cost products that are not usually dispensed in retail pharmacies but require special handling and a complex pharmaceutical regime. The company is focused on diseases such as Sickle Cell Anemia, Cancer, HIV/Aids, Hepatitis C., Multiple Sclerosis, Hemophilia and Drug addiction.
PPSI (PHYSICIAN AND PHARMACEUTICAL SERVICES, INC.) a subsidiary of Univec promotes and pays for pharmaceutical products though its network of pharmacies. PPSI eliminates the need for the pharmaceutical companies to distribute actual drug samples to physicians reducing potential liability for the physician while maintaining clinical oversight and drug interaction checks for the patient. The company through it’s “StarterScript” allows in lieu of a physician sample, a voucher or a co-payment card to be provide to the patient for a trial supply of medication redeemed in any of the nearly 55,000 retail pharmacies utilizing the PPSI real-time processing system.
UNVC .0004's getting hit hard
15 million x 4 million a little more volume and we'll be seeing .0005's
UNVC .0004's getting hit! 17 mil x 5 mil
UNVC running on news! .0004's up and thin
http://syndicate.pinksheets.com/stock/UNVC/news/UNIVEC-announces-entry-into-Transdermal-Patch-Marketplace?id=41371&b=y
UNVC .0004's up ask getting hit hard on news!
http://syndicate.pinksheets.com/stock/UNVC/news/UNIVEC-announces-entry-into-Transdermal-Patch-Marketplace?id=41371&b=y
.0004's up!
ask getting hit hard now
UNVC huge bid support ask getting hit hard on news!
http://syndicate.pinksheets.com/stock/UNVC/news/UNIVEC-announces-entry-into-Transdermal-Patch-Marketplace?id=41371&b=y
UNVC .0003's are down, news out!
UNVC news today, this is going to get big
http://syndicate.pinksheets.com/stock/UNVC/news/UNIVEC-announces-entry-into-Transdermal-Patch-Marketplace?id=41371&b=y
NEWS!!!! Congrats for those who bought in last week, this is going to get huge. This is why you watch for accumulation
http://www.otcmarkets.com/stock/UNVC/news?id=41371
UNIVEC announces entry into Transdermal Patch Marketplace.
Owings Mills, Maryland —January 17, 2012– Univec, Inc. (UNVC) a specialty pharmaceutical company, announces it has entered into the transdermal patch marketplace with the provision of Nicotine Replacement Therapy patches. Nicotine Replacement Therapy involves the use of products that provide low doses of nicotine but do not contain the toxins found in smoke. The goal is to relieve cravings for nicotine and ease the symptoms when someone stops using cigarettes and smokeless tobacco. Transdermal patch is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream.
David L. Dalton, President and CEO of Univec stated. “ We are delighted to continue making progress in our new business model. The National Drug Codes received from the FDA allows Univec to builds it’s own brand of products. The Transdermal patch can be used for different drug delivery system. It is a foundation to build and grow the company on some of our existing markets. We thank our associates, shareholders and investors for the support, confidence and patience they have shown the company. ”
About Univec
Univec, Inc. A minority business enterprise (MBE) is a Specialty Pharmaceutical Company that manufactures and distributes high cost Specialty Pharmaceuticals. Specialty Pharmaceuticals are high cost products that are not usually dispensed in retail pharmacies but require special handling and a complex pharmaceutical regime. The company is focused on diseases such as Sickle Cell Anemia, Cancer, HIV/Aids, Hepatitis C., Multiple Sclerosis, Hemophilia and Drug addiction.
PPSI (PHYSICIAN AND PHARMACEUTICAL SERVICES, INC.) a subsidiary of Univec promotes and pays for pharmaceutical products though its network of pharmacies. PPSI eliminates the need for the pharmaceutical companies to distribute actual drug samples to physicians reducing potential liability for the physician while maintaining clinical oversight and drug interaction checks for the patient. The company through it’s “StarterScript” allows in lieu of a physician sample, a voucher or a co-payment card to be provide to the patient for a trial supply of medication redeemed in any of the nearly 55,000 retail pharmacies utilizing the PPSI real-time processing system.
Forward Looking Statements
This document may contain forward-looking statements based on current expectations that could be affected by the risks and uncertainties involved in Univec’s business. These risks and uncertainties include, but are not limited to, the risks described from time to time in Univec’s reports to the General Public and reporting agencies. Subsequent written or oral statements attributable to Univec or persons acting on its behalf are expressly qualified in their entirety by the cautionary statements in this document and those in Univec’s reports filed
Looks like it could have a nice bounce based on technicals and momo alone. Its a penny stock, it doesn't need anything from the company to have a great. Get in early and get out early. This stock has a reputation for large runs so once it gets going there will be a lot of people trying to get in which is why I expect an easy 5 bagger from here. The CEO diluted because thats how every penny stock works, we all know this. I'm expecting a run soon based on the past month of accumulation, the low float, relatively little resistance on the ask side, and of course past history.
UNVC large buy at .0003
UNVC large buy at .0003
Big 2.5 million hit on the ask
UNVC .0003 getting hit
Another hit at .0003
UNVC only $9k on the ask and then up to .0004. This could move fast
UNVC 23.7 million on the bid now
UNVC bid at 23.7 million now
bid up to 22.7 million now
good to see you lottotix
UNVC looks like this is ready to run, good volume today up 50%
UNVC 15 million on the bid now!
UNVC 15 million on the bid now!
Nice bid support!
UNVC .0003 up
UNVC .0003 up
UNVC .0003 getting hit
Based on the chart if there has been any recent dilution it hasn't been very bad